BusinessEconomyStock Market

Serum Institute of India Produces Over 10 Crore Doses of COVID-19 Vaccine Covishield in June 2021

2 Mins read

New Delhi, June 27: Fulfilling its commitment, Serum Institute of India has produced over 10 crore doses of its COVID-19 vaccine Covishield in June thus far as India ramps up the pace of its vaccination drive within the face of a possible third wave of the virus infection.

India’s COVID-19 inoculation drive has picked up pace under the new phase of universalisation of COVID-19 vaccination that commenced on the summer solstice with around 69 lakh vaccine doses being administered on a mean daily within the last six days.

The immunisation data published at 7 am on Sunday showed that India administered 64.25 lakh vaccine doses during a day, taking the cumulative number of jabs given thus far under the nationwide inoculation drive to 32.17 crores. COVID-19 Vaccine Makes Vaccinated Person Detectable Via Bluetooth? Fake Claim Goes Viral, Here’s the reality.

According to information provided to the Drugs Controller General of India (DCGI) by the Pune-based Serum Institute of India, it’s sent 45 batches of Covishield, amounting to 10.80 crore doses, to the Central Drugs Laboratory, Kasauli for release in June thus far.

The firm’s Director at Government and Regulatory Affairs, Prakash Kumar Singh, had in May communicated to Union Home Minister Amit Shah that Covishield production would be ramped up to 10 crore doses in June.

“We are committed to enhancing the assembly capacity of our Covishield vaccine and are working round-the-clock in spite of varied challenges being faced by us due to the COVID-19 pandemic.

“We are pleased to tell that within the month of June we’ll be ready to manufacture and provide nine to 10 crore doses of our Covishield vaccine to our country as compared to our present production capacity of 6.5 crore doses in May,” Singh had said during communication to Shah.

The nationwide vaccination drive has been ramped up through the availability of more vaccines, advanced visibility of vaccine availability to states and Union Territories enabling them to plan better, streamlining the vaccine supply chain, consistent with the Health Ministry.

Under the revised guidelines, vaccine doses are provided freed from cost by the Centre and are allocated to states and Union Territories supported criteria like population, disease burden, and therefore the progress of vaccination. The Centre procures 75 percent of the vaccines being produced within the country. All above the age of 18 years are eligible for free-of-charge vaccine doses. COVID-19 Vaccine Update: SII Begins Manufacturing of Novavax’s Protein-Based Vaccine Covovax; to start out Trial in Kids in July.

The Centre had earlier allowed states and personal hospitals to acquire 50 percent of the vaccines following demands for decentralisation of the method. However, after several states complained of problems including funding, Prime Minister Narendra Modi announced the revised vaccine guidelines.

In order to incentivise production and encourage new vaccines, domestic manufacturers are given the choice to supply vaccines to private hospitals. this is often restricted to 25 percent of their monthly production under the new guidelines.

Related posts

India's second COVID-19 wave has likely peaked: Nomura report

1 Mins read
The second wave of the pandemic in India is more of a humanitarian crisis instead of an economic one and is probably going to possess peaked, a Japanese brokerage said on Thursday.   Covid 19 …

IAF aircraft with 4 cryogenic oxygen tanks from Singapore to reach India today

2 Mins read
Union defence minister Rajnath Singh on Saturday reviewed the defence ministry’s effort to affect this pandemic situation within the country as IAF planes are crisscrossing the skies ferrying oxygen. A C-17 aircraft of the Indian…
Get the latest updates by subscribing to us

Subscribe to us for getting the benefits of climbstreet and latest updates

Leave a Reply

Your email address will not be published. Required fields are marked *